Nektar Therapeutics reported positive Phase 2b results for rezpegaldesleukin (rezpeg) in treating atopic dermatitis, marking a significant clinical milestone for the biologic drug. The drug demonstrated improvements in eczema severity metrics during a 16-week induction period. However, cross-trial analyses suggest that rezpeg's efficacy may not yet surpass that of Dupixent, the current top biologic for atopic dermatitis. Despite this, investor enthusiasm was evident following the announcement, with notable stock price gains. Additional continued research and data readouts remain anticipated in this competitive therapeutic area.